



Prevention of Pandemic-associated Pathology Munich

P³M



Prof. Andreas Pichlmair
Institute of Virology, TUM



Prof. Percy Knolle
Inst. f. Mol. Immunology



Prof. Dietmar Zehn
Inst. f. Animal physiology
and immunology



Prof. Andreas Pichlmair
Inst. f. Virology



Prof. Ulrike Protzer
Inst. f. Virology



Prof. Fabian Theis
Inst. f. Computational
Biology



Prof. Oliver Keppler
Max v. Pettenkofer
Institute



Fighting a pandemic requires three pillars

- Pandemic situation -
reduce impact on economy and society

Prevention of dissemination

Quarantine
Lockdown
Surveillance

Little acceptance
in Society

**Severe economic
impact
Enormous costs**

Vaccination

Slow development

Not guarantee of
success

Emergence of viral
variants

Vairable acceptance

**Very high
economic potential**

Prevention of severe diseases

Predictive markers?
Predict severity of
disease, epidemiology

**Targeted, causal
therapties?**
Identification of
disease mechanisms

**Very high
economic potential**

Existing

Missing

„One Munich strategy“

Prevention of Pandemic-associated Pathology Munich

P³M

One Munich Strategy




HELMHOLTZ
MUNICH

Research focus Areas

- Pathogenicity driven by virus
- Pathogenicity elicited by the host
- Development of AI-based disease models

Prevention of Pandemic-associated Pathology Munich


I.



Viral pathogenicity

*Which cells are infected?
Which organs are affected?
What are the hallmarks of infection,
how can infection be prevented?*

II.



Immunopathogenicity


*Which immune reactions protect,
Which ones are damaging?
How to discriminate protective from
damaging immune responses?
how can infection be prevented?*

III.



Systems analysis (predictive models)

*Which cellular signalling networks are affected
How can data be used as guidance for*



Predictive activities of drugs (or genes)?


Viruses





Humans



„3 body problem“






Drugs




- Identification of MPXV-driven perturbations on the host
- Identification of kinases that are differentially active in MPXV-infected cells
- Identification of potential drug targets and drugs that are active against poxviruses

Interactome and effects of individual viral proteins



Stukalov et al., Nature 2021
 Scaturro et al., Nature 2018
 Bergant et al., EMBO J, 2022
 Bergant et al., Nat Comms, 2023
 Huang et al., in revision

Huang et al, in revision
 With Gerd Sutter, Ulla Protzer 7



➔ Prediction of disease progression?

➔ Prediction of successful perturbation strategies?

**Goal: appropriate and fast countermeasures in case of a pandemic
in cooperation with industry partners**

- **Basic financing to set up necessary scientific structures**
- **Step-wise establishment of an academic network based on core competences and collaborations with pharma and biotech partners**
- **Sustainable development of pharma/biotech collaborations in Munich, enforcing bavaria being a strong location for pharma with international connections**

Bottlenecks

- **Data storage capacity, computational infrastructure**

Innovative diagnostics and therapies through predictive markers

Data base of infection-associated perturbations based on model systems and defined clinical data

AI based analysis of multi-omics data

Identification of patients at risk

Personalized treatment of patients at risk

Identification of predictive biomarkers and therapies



P³M



HELMHOLTZ MUNICH



Prof. Percy Knolle
Inst. f. Mol. Immunology

Prof. Dietmar Zehn
Inst. f. Animal physiology and immunology

Prof. Andreas Pichlmair
Inst. f. Virology



Prof. Ulrike Protzer
Inst. f. Virology

Prof. Fabian Theis
Inst. f. Computational Biology



Prof. Oliver Keppler
Max v. Pettenkofer Institute